Hypogonadal hypertension in male Sprague-Dawley rats is renin-angiotensin system-dependent: role of endogenous androgens

Andrea E. Hanson¹, Mercedes Perusquia² and John N. Stallone¹,³*

Abstract

Background: Acutely, testosterone (TES) and other androgens are efficacious vasodilators, both in vitro and in vivo; however, their long-term effects on arterial blood pressure (BP) remain unclear. It was hypothesized that endogenous androgens exert long-term anti-hypertensive effects on systemic BP through a combination of genomic and nongenomic effects to enhance vasodilation of the systemic vasculature.

Methods: The long-term effects of endogenous TES and exogenous TES replacement therapy (TRT) on BP were studied in intact (InT) and castrated (CsX) male Sprague-Dawley (SD) and testicular-feminized male (Tfm, androgen receptor defective) rats (12 weeks old). Systolic BP (tail-cuff plethysmography) was determined weekly for 15 weeks in InT-control and CsX rats. Some CsX-SD rats received androgen replacement therapy at 10-15 weeks with TES-enanthate (TRT; 1.75 mg/kg, 2x/week) or DHT-enanthate (DRT; 1.00 mg/kg, 2x/week) and a separate group of CsX-SD rats received losartan-potassium in drinking water (LST, 250 mg/L) for the entire 15 week period. Expression of renin, angiotensinogen (Agt), angiotensin converting enzyme (ACE), and angiotensin II type I receptor (AT₁R) mRNA in kidney and aorta were determined by real-time PCR (rt-PCR) and plasma renin levels were determined by radioimmunoassay.

(Continued on next page)
Background
Cardiovascular disease (CVD) is a major cause of morbidity and mortality worldwide, and in the Western World, one-third of all deaths are attributed to CVD [1]. One of the most conspicuous characteristics of this serious healthcare problem is that most forms of CVD are higher in men than in age-matched premenopausal women, yet the reasons for these obvious sex differences remain poorly understood. The clinical studies and epidemiological observations that hypertension (HT) and coronary artery disease (CAD) occur more frequently in men than in premenopausal women [2–8] have led to the dogmatic view that testosterone (TES) and other androgens exert deleterious effects on the heart and vasculature, and exacerbate the development of CVD in men [9–11]. Indeed, the literature is replete with reports of the beneficial effects of estrogen on the female cardiovascular system [12–14]. In contrast, TES is usually considered to exacerbate CVD in males [9, 10, 15, 16]. In parallel, most animal studies in the past have provided support for the dogmatic view that TES exacerbates CVD [17–21]. For example, studies in both genetic (Dahl salt-sensitive and spontaneously hypertensive) and induced (DOCA-salt) rat models of HT reveal that castration ameliorates the development of HT in males [17, 22, 23].

However, more recent clinical and epidemiological studies on the role of TES in CVD are at best controversial, and in-depth reviews and analyses of the role of androgens in CVD reveal that there is little sound evidence that TES, or other androgens, shorten men’s lives [6, 8]. Interestingly, clinical studies over 70 years ago first documented the beneficial effects of TES on the cardiovascular system. Acute intramuscular injections of TES were used successfully in the treatment of angina pectoris in men with CAD [24–26], and for HT and peripheral vascular disease [26, 27] and were thought to involve vasodilation. Further, more recent clinical studies demonstrated that acute intracoronary injection or infusion of TES in men with CAD improves myocardial ischemia and increases coronary arterial dilation and blood flow [28–30].

In parallel, accumulating evidence from more recent animal studies employing isolated blood vessels in vitro, reveals that TES and other androgen metabolites exert beneficial effects by inducing acute vasorelaxation through rapid, nongenomic mechanisms in a variety of large arteries, as well as smaller resistance arteries, and at physiological as well as pharmacological concentrations (for reviews, see [31, 32]). There is also more limited evidence that TES and other androgens produce coronary or systemic vasodilation in humans [30] and in canine [33], porcine [34, 35], and rodent animal models [36]. Together, these in vitro and in vivo studies reveal that androgen-induced vasodilation is a structurally specific, nongenomic effect, with efficacies and potencies fundamentally different from those for the genomic effects of androgens on reproductive targets [31, 37–40].

Although the mechanisms underlying the acute vasodilatory effects of TES have been established in vitro and to a lesser extent in vivo, little is known about the long-term systemic effects of TES on blood pressure (BP). Thus in the present investigation, the long-term effects of endogenous and exogenous TES on arterial BP were determined in male Sprague-Dawley (SD) and testicular-feminized male [androgen receptor (AR)-deficient; Tfm] rats. The hypothesis tested was that endogenous androgens exert long-term anti-hypertensive effects on systemic BP through a combination of genomic and nongenomic effects to enhance vasodilatation of the systemic vasculature. The results reveal that TES exerts clear anti-hypertensive effects on systemic BP that appear to involve genomic as well as nongenomic effects.
on the vasculature and kidney through inhibition of renin-angiotensin system expression.

**Methods**

**Ethical approval**

The animal use protocols for these studies were written in accordance with regulations of the Office of Laboratory Animal Welfare of the National Institutes of Health, and were reviewed and approved by the Texas A&M University Institutional Animal Care and Use Committee (IACUC).

**Experimental animals**

Ten-week-old male Sprague-Dawley (SD) rats were purchased from Envigo (Houston, TX) and housed at the Laboratory Animal Resource and Research facilities at Texas A&M University in College Station, TX. The rats were maintained in well-ventilated rooms with controlled temperatures (21-26 °C), controlled relative humidity (~50%), and controlled photoperiod (12:12-h light:dark cycle). Animals were pair housed in standard plastic laboratory rat cages and fed a 16% protein rat chow that was soybean- and alfalfa-free (Teklad Global diet; Houston, TX). This diet is nominally free of dietary phytoestrogens, as ingested phytoestrogens have been reported to confound studies investigating sex differences in vascular function [41]. Water was provided ad libitum. The rats were randomly divided into one of three experimental groups: intact controls (InT-controls), castrated (CsX), or castrated with TES replacement therapy (CsX-TRT). Following arrival at Texas A&M University, all rats were acclimated to new housing for 4-5 days and then trained daily for handling and tail-cuff blood pressure recording for 7-10 days (see below), so that all rats were 12 weeks of age at the start of the experiments. One experimental group of SD rats studied (CsX-DRT, see below) were obtained from first-generation Envigo stock bred in-house, but were otherwise housed, handled, and treated identically as the rats obtained directly from Envigo. These rats were estimated to be 14 weeks of age at the start of the experiments.

Parallel studies using age-matched Tfm rats were used to separate the nongenomic and genomic effects of TES. This rat breed was originally derived from the King/Holtzman strain and affected males (termed Tfm rats) exhibit a recessive X-linked single gene mutation, leading to a defective cytosolic androgen receptor (AR) that eliminates the classical genomic effects of TES [36, 45, 46]. A breeding colony of these animals was established at Texas A&M University by breeding carrier female King/Holtzman stock to male SD rats and the resulting F1 carrier females were then bred to male SD rats; the resulting F2 Tfm males were used in the present experiments. Affected Tfm rats were randomly divided into one of three experimental groups: InT-control, CsX or CsX-TRT and experiments were initiated at 12 weeks age.

**Surgical procedures (bilateral orchiectomy)**

Male SD rats in CsX and CsX-TRT groups underwent bilateral orchiectomy, using standard surgical procedures at 12 weeks age. Briefly, animals were pretreated with atropine sulfate (0.05 mg kg\(^{-1}\); sc) and anesthetized with isoflurane. Ophthalmic ointment was applied to the eyes of each animal as a preventative for corneal dryness. During the entire surgical procedure, animals were provided supplemental heat via a heating pad and continuously monitored for changes in respiratory rate, membrane color, and reflex response to ensure an adequate surgical plane of anesthesia. The surgical site was clipped, aseptically prepared, using alternating scrub cycles of iodine and 70% isopropyl alcohol, and the area was covered with a surgical drape. A single 1-2 cm incision was made in the scrotum and the muscular cremaster tunica which encloses each testis was bluntly dissected. Additional 1 cm incisions were made through the left and right tunics to externalize each of the testes. The spermatic cords were ligated with 1-0 surgical silk suture, transected, and the cut ends were swabbed with betadine and allowed to retract into the tunic. The tunics were sutured closed with absorbable sutures (Ethicon 4-0 Vicryl\(^{\circ}\), and the scrotum was closed with 3-5 absorbable sutures (Ethicon 4-0 Vicryl\(^{\circ}\)). Banamine (2.5 mg kg\(^{-1}\); im) was administered for analgesia and the animals were transferred to a recovery cage.

Tfm rats in the CsX and CsX-TRT groups also underwent bilateral orchiectomy at 12 weeks age. Castration of Tfm rats involves a laparotomy to remove the abdominal testes in these animals. A small incision (2 cm) was made through the abdominal wall and the testicular arteries were isolated, ligated, and transected and the testes were then removed. The body wall musculature was closed with 3-4 absorbable sutures (Ethicon 4-0 Vicryl\(^{\circ}\)), and the skin was closed with 3-4 stainless steel wound clips.

**Systolic blood pressure**

Systolic BP was recorded using a non-invasive tail-cuff plethysmography system (IITC Life Science; Woodland Hills, CA) connected to a Power Lab Data Acquisition
System and analyzed with the Lab Chart Software (AD Instruments; Colorado Springs, CO). Prior to data collection, animals were acclimated to daily handling and the tail-cuff procedure for 7-10 days and trained to rest quietly in a darkened cylindrical restraint warmed (30 °C) to maximize the tail blood flow signal. Week 0 systolic BP and body weight (BW) were recorded as baseline (time 0) data for each animal prior to castration or experimental treatments at 12 weeks age, and then weekly for 15 weeks following castration surgery.

Experimental design

Weekly measurements of systolic BP and BW of Int, CsX and CsX-TRT SD, and Tfm rats began prior to CsX surgery (= baseline, time 0) and then resumed 7 days following surgery, and continued for the entire 15-week experimental period. Following BP and BW measurements on week 10, CsX-TRT rats began receiving bi-weekly injections of TES-enanthate dissolved in 90% olive oil/10% DMSO vehicle (1.75 mg kg\(^{-1}\), sc). CsX animals not receiving androgen therapy received bi-weekly injections of the olive oil-DMSO vehicle at equivalent volumes to the TES-enanthate. Systemically, TES can be reduced to dihydrotestosterone (DHT) or aromatized to estradiol (E\(_2\)). To confirm that the observed effects of TES on BP regulation did not result from conversion to E\(_2\), the TES metabolite, 5α-DHT, which cannot be aromatized to E\(_2\), was administered as the androgen therapy in a separate group of CsX male SD rats (CsX-DRT). Following BP and BW measurements on week 10, CsX-DRT rats began bi-weekly injections of DHT-enanthate dissolved in 90% olive oil/10% DMSO vehicle (1.00 mg/kg; sc). CsX animals not receiving androgen therapy received bi-weekly injections of the olive oil-DMSO vehicle at equivalent volumes to the TES-enanthate. Systemically, TES can be reduced to dihydrotestosterone (DHT) or aromatized to estradiol (E\(_2\)). To confirm that the observed effects of TES on BP regulation did not result from conversion to E\(_2\), the TES metabolite, 5α-DHT, which cannot be aromatized to E\(_2\), was administered as the androgen therapy in a separate group of CsX male SD rats (CsX-DRT). Following BP and BW measurements on week 10, CsX-DRT rats began bi-weekly injections of DHT-enanthate dissolved in 90% olive oil/10% DMSO vehicle (1.00 mg/kg; sc).

In a separate group of SD rats, losartan (LST), an angiotensin II type 1 receptor (AT\(_1\)R) antagonist, was used to investigate the role of the renin-angiotensin-aldosterone system (RAS) in androgen-dependent changes in BP. Male rats were randomly assigned to one of three groups: CsX, CsX-LST, or CsX-LST-TRT. Animals were acclimated to weekly systolic BP measurements, and CsX animals underwent bilateral orchectomy surgery as described previously. CsX-LST and CsX-LST-TRT groups received ad libitum drinking water with LST-potassium (250 mg L\(^{-1}\)). Weekly systolic BP and BW were recorded for CsX, CsX-LST, and CsX-LST-TRT rats for the entire 15-week experimental period. CsX-LST-TRT animals began bi-weekly subcutaneous injections of TES-enanthate (1.75 mg kg\(^{-1}\); sc, 2x/week) following BP and BW measurements on week 10. CsX and CsX-LST animals not receiving androgen therapy received equivalent volumes of the olive oil-DMSO vehicle-control (sc, 2x/week).

Plasma hormone concentrations

Animals were humanely euthanized via rapid decapitation at weeks 10 or 15 for plasma and tissue collection. Rapid decapitation minimizes potential neural and hormonal artifacts that result during anesthesia and euthanasia [47]. Trunk blood was collected in chilled 13 × 100 mm borosilicate glass test tubes containing 100-200 units of heparin sodium and immediately centrifuged at 10,000 RPM for 5 min to separate cells from plasma. The resultant plasma was frozen and stored at −80 °C for later analysis. Selective radioimmunoassays were used to assess plasma concentrations of TES and total estrogens (MP Biomedicals, LLC; Santa Ana, CA). Plasma renin was analyzed by Core Lab Facilities at Wake Forest University (Winston-Salem, NC). Plasma renin concentrations are defined as the rate of Ang I generated by renin in the plasma sample. In the presence of excess exogenous angiotensinogen isolated from nephrectomized rat plasma, renin concentrations were determined by incubating samples at a pH 6.5 for 90 min and quantifying Ang I by radioimmunoassay (Cisbio Bioassays; Codolet, France).

RAS mRNA expression in the male rat aorta and kidney

The kidneys and thoracic aorta were collected from Int-control, CsX, and CsX-TRT rats at 0, 10, and 15 weeks and analyzed for RAS component mRNA expression by real time-polymerase chain reaction (rt-PCR). Following euthanasia, the thoracic aorta was immediately isolated, snap frozen in liquid nitrogen, and stored at −80 °C. The left kidney was isolated, cleaned of connective tissue and fat, sectioned, snap frozen on dry ice, and stored at −80 °C. Portions of the aorta and kidney samples (0.3-0.5 g) were used to analyze angiotensinogen (Agt), angiotensin-converting enzyme (ACE), AT\(_1\)R, and renin mRNA expression using previously established rt-PCR methods [48]. Briefly, total RNA was isolated using the RNeasy Plus Mini Kit (Qiagen), according to manufacturer’s instructions. Individual RNA samples were tested for potency and total purified RNA samples (900-1500 ng) were seeded into a reverse transcription reaction using the SuperScript II system (Invitrogen), according to the recommended protocol for the high-capacity cDNA reverse transcription kit (Invitrogen), by combining 2.0 μL random hexamer oligonucleotides, 0.8 μL of 100 mM dNTP, 2.0 μL RT buffer, 1.0 μL MultiScribe™ reverse transcriptase, and 4.2 μL purified RNA plus water. Samples were brought to 25 °C for 5 min, 42 °C for 50 min, 45 °C for 20 min, 50 °C for 15 min, and 70 °C for 5 min. Relative levels of candidate gene transcripts were analyzed using the Dynamo Flash SYBR Green qPCR (Thermo Scientific), according to the recommended protocol. Reactions were quantified on a CFX384 touch RT-PCR detection system (BioRad). The primers for Agt, ACE, AT\(_1\)R, renin, and Elongation Factor-1 (EF-1; reference gene) are listed in Table 1.
Effects of androgens on systolic BP

The role of the RAS in the development of castration-induced hypertension is summarized in Fig. 2. Systolic BP declined significantly in CsX SD rats treated with the AT1R antagonist, losartan-potassium in the drinking water (CsX-LST; 250 mg L⁻¹). Systolic BP declined until week 4 (CsX-LST, 100 ± 1.5 vs. CsX, 124 ± 2.6 mmHg; P ≤ 0.001), and remained significantly lower throughout the 15-week experimental period (CsX-LST, 99 ± 0.4 vs. CsX, 140 ± 1.2; P ≤ 0.0001). BP in an additional CsX-LST group also treated with TRT from weeks 10 to 15 (CsX-LST-TRT, 101 ± 0.8, data not shown) did not differ from CsX-LST (99 ± 0.4; P > 0.05). CsX rats receiving DHT androgen therapy (CsX-DRT) from weeks 10 to 15 exhibited declines in systolic BP that normalized identically to those of CsX-TRT rats (CsX-DRT, 114 ± 1.3 vs. CsX-TRT, 113 ± 1.3; P > 0.05).

Results

Effects of castration and androgen therapy on systolic blood pressure

Systolic BP of InT-control rats averaged 109 ± 3 mmHg at week 0. The repeated measures ANOVA revealed that BP differed significantly among the treatment groups and within each treatment group over time (P < 0.001). BP increased slightly the first 2 weeks of the experimental period and then maintained a stable plateau average of 114 ± 5 mmHg for the remainder of the 15-week experiment. In contrast, systolic BP of CsX rats exhibited a progressive and significant increase from week 0 (109 ± 3.0) to a maximal pressure at week 9 (143 ± 3.5), which then plateaued from weeks 10 to 15. Systolic BP of CsX at week 15 (140 ± 1.2) was significantly higher than InT-control (113 ± 0.3; P ≤ 0.0001). In a separate group of CsX, TRT administered from weeks 10 to 15 resulted in a progressive decline in systolic BP which completely normalized by week 15 to levels virtually identical to those of InT-control rats (CsX-TRT, 113 ± 1.3 vs. InT-control, 113 ± 0.3; P > 0.05). The effects of CsX on systolic BP were also determined in AR-deficient Tfm rats. Similar to the SD rats, castration of Tfm rats increased systolic BP, while TRT fully normalized BP. In contrast to the SD rats, Tfm rats exhibited a delay in the initial development of hypertension, but a more rapid onset of hypertension from weeks 5-10, compared to SD rats. Prior to CsX, systolic BP of CsX-Tfm rats averaged 109 ± 0.7 at week 0; following CsX, BP increased progressively and plateaued by week 10 (139 ± 0.4) and was fully normalized by TRT at week 15 (106 ± 2.8). TRT in Tfm rats resulted in a distinctly more rapid and greater overall decline in systolic BP compared to CsX-TRT SD rats. Weekly systolic BPs of InT-control, CsX, CsX-TRT, and CsX-TRT-Tfm are shown in Fig. 1.

Mechanisms underlying anti-hypertensive effects of androgens on systolic BP

The following drugs and reagents were used: TES-enanthate (17β-hydroxy-4-androsten-3-one-enanthate) and 5α-DHT-enanthate (17β-hydroxy-5α-androstan-3-one-enanthate; Steraloids; Newport, RI); and losartan-potassium (Selleck Chemical, Houston, TX). All other chemicals were of reagent grade quality and were purchased from Sigma Chemical (St Louis, MO). TES-enanthate and 5α-DHT-enanthate for androgen therapy experiments were dissolved in 90% olive oil/10% DMSO at 5.0 mg/ml.

Data analyses

All data are expressed as the means ± standard error of the mean (SEM) and n indicates the number of animals in each experiment. BP data groups were first subjected to a two-way analysis of variance (ANOVA) with repeated measures to detect significant differences in BP among treatment groups (Int, CsX, CsX-TRT, CsX-DRT, CsX-LST, CsX-LST-TRT, and CsX-TRT-Tfm) and their interactions over time (0-15 weeks). BP data groups at key time points (0, 5, 10, 15 weeks) and other data groups (e.g., plasma renin or mRNA data) were first subjected to a one-way ANOVA to detect significant differences among means of the experimental groups; differences among means were accepted as significant if P value < 0.05. If the main effects were identified by the ANOVA, then pair-wise Student’s t tests were performed on group means to detect significant pair-wise differences among the means of the various experimental groups. A Bonferroni correction was employed for type I errors associated with multiple comparisons and differences between the means. Differences between any two means were accepted as significant if P < 0.05.
reduced plasma renin concentration to levels similar to those of InT-control rats ($P > 0.05$).

**Effects of castration and androgens on expression of mRNA of RAS components**

mRNA expression of RAS components, as measured by rt-PCR, in the kidney and aorta of InT-control, CsX, and CsX-TRT male SD rats are shown in Fig. 4. In the kidney, CsX significantly increased expression of mRNA for renin (92%), AT$_1$R (80%), and ACE (58%) compared to InT-control rats ($0.0013 \leq P \leq 0.033$), while TRT normalized expression of mRNA for renin, ACE, and AT$_1$R to levels similar to those of InT-control rats ($P > 0.05$). In contrast, expression of mRNA for renal Agt was
reduced by 55% in CsX rats compared to InT-control rats ($P \leq 0.0006$), while TRT restored expression of Agt mRNA to 73% of InT-controls ($P \leq 0.01$). In the thoracic aorta, neither CsX nor CsX-TRT had any statistically significant effects on expression of mRNA for renin, ACE, AT$_1$R, or Agt ($P > 0.05$).

Effects of androgens on body weight and seminal vesicle weight

Body weight (BW) and seminal vesicle (SV) weight for the seven experimental groups are summarized in Table 2. Week 0 BW was slightly lower in the InT-controls and higher in CsX-DRT compared to the other five experimental groups; however, BW increased similarly in all groups over the 15-week experimental period. BW was uniformly similar among most experimental groups at weeks 10 and 15, except for CsX-DRT and CsX-TES-Tfm, which were significantly higher ($P \leq 0.0001$). Treatment with LST had no effect on BW ($P > 0.05$). SV weight varied significantly among the seven experimental groups (0.0001 $\leq P \leq 0.0201$). Castration reduced SV weight by more than 90% compared to InT-control rats ($0.02 \pm 0.001$ g·100 g BW$^{-1}$ vs. $0.29 \pm 0.013$), while SV weight in the CsX-TRT rats ($0.33 \pm 0.018$) was fully restored and comparable to that of InT-control rats ($P > 0.05$). In contrast, DHT therapy only partially restored SV weight compared to CsX-TES rats ($P < 0.05$). Treatment with LST had no effects on SV weight in either CsX-LST or CsX-LST-TRT rats ($P > 0.05$).

Effects of castration and androgen therapy on plasma sex hormone concentrations

The effects of castration and androgen therapy on plasma TES and estrogen concentrations are summarized in Table 3. As expected, castration drastically reduced the plasma TES concentration of CsX rats compared to InT-control male rats, while TRT restored plasma TES to levels similar to those of InT-control rats ($P > 0.05$). Plasma TES concentrations of CsX and CsX-LST rats were below detectable limits of the TES radioimmunoassay ($< 0.01$ ng mL$^{-1}$). Plasma total estrogen concentrations were low among all experimental groups and were not significantly altered by CsX, TRT, or LST treatment ($P > 0.05$).

Discussion

In the present investigation, the long-term effects of endogenous and exogenous TES on systemic BP were studied in male SD and Tfm rats. The results reveal that endogenous as well as exogenous androgens (TES and 5α-DHT) exert novel long-term anti-hypertensive effects on systemic BP that appear to involve estrogen-independent, nongenomic, and possibly genomic mechanism(s), which reduce RAS expression in the kidney. Thus, the long-term anti-hypertensive effects of TES may involve enhanced fluid and electrolyte excretion as well as systemic vasodilation. Castration of InT-control male SD rats resulted in a dramatic reduction in plasma TES concentration and seminal vesicle mass (an important target tissue for TES), while TRT restored plasma TES concentration and seminal vesicle mass to nearly identical values as InT-control male SD rats. Additionally, there were no significant differences in plasma total estrogen concentrations among InT-control, CsX, and CsX-TRT male SD rats. Thus, TRT provided physiological replacement of circulating TES concentrations without any measurable changes in plasma estrogen levels. While the dose of TES therapy employed in the present study produced physiological concentrations and biological effects on reproductive target tissues (i.e., SV mass), the dose of DHT employed for androgen therapy only partially restored SV mass. Thus, the dose of DHT employed was either too low and/or systemic administration of DHT may not be as effective as the local conversion of TES to DHT that occurs within the SV, since DHT is a local tissue hormone and not a circulating systemic androgen. It should be noted, however, that the dose of DHT employed did exert virtually identical anti-hypertensive effects on systemic BP as TES over the 5 week treatment period; thus, the anti-hypertensive effects of TES observed in the present studies do not likely involve aromatization of TES to estrogen.
Fig. 4 rt-PCR for mRNA expression of renin-angiotensin system (RAS) components in the kidneys of male Sprague-Dawley (SD) rats: intact (InT-control), bilaterally castrated (CsX), or CsX with TES therapy (CsX-TRT; 1.75 mg kg$^{-1}$; sc, 2x/week). Values are expressed as the ratio of RAS component mRNA to elongation factor-1 (EF-1) mRNA levels obtained from the same tissues. Bars represent means ± SEM ($n$ = 6-9 rats per group). a, b, and c indicate the mean values for mRNA expression of renin, angiotensinogen (Agt), angiotensin-converting enzyme (ACE), or angiotensin II receptor type I (AT1R) among the three experimental groups (InT-Control, CsX, and CsX-TRT) without common script are significantly different (0.0013 ≤ $P$ ≤ 0.033).

Table 2 Body weight (BW) and seminal vesicle weight of InT-control, CsX, CsX-TRT, CsX-DRT, CsX-LST, CsX-LST-TRT, and CsX-TRT-Tfm male rats

| Group        | Week 0, BW (g) | Week 10, BW (g) | Week 15, BW (g) | Seminal vesicle (g·100 g of BW$^{-1}$) |
|--------------|----------------|-----------------|-----------------|----------------------------------------|
| InT-control  | 339 ± 8a       | 433 ± 12b       | 439 ± 14a       | 0.29 ± 0.013a                          |
| CsX          | 383 ± 22b      | 457 ± 22a       | 458 ± 27a       | 0.02 ± 0.001c                          |
| CsX-TRT      | 374 ± 7b       | 433 ± 7a        | 446 ± 8a        | 0.33 ± 0.018a                          |
| CsX-DRT      | 519 ± 13c      | 594 ± 17c       | 670 ± 26c       | 0.10 ± 0.003d                          |
| CsX-LST      | 385 ± 4b       | 456 ± 8a        | 462 ± 11a       | 0.03 ± 0.001b                          |
| CsX-LST-TRT  | 374 ± 3c       | 432 ± 4a        | 453 ± 5a        | 0.34 ± 0.025a                          |
| CsX-TRT-Tfm  | 401 ± 23b      | 487 ± 16a       | 525 ± 20a       |                                         |

Male Sprague-Dawley (SD) rats: intact (InT), bilaterally castrated (CsX), and CsX with TES therapy (CsX-TRT; 1.75 mg kg$^{-1}$; sc, 2x/week) or DHT therapy (CsX-DRT;1.00 mg kg$^{-1}$; sc, 2x/week). In a separate experiment, CsX males were given losartan drinking water (250 mg L$^{-1}$) without (CsX-LST) or with TES therapy (CsX-LST-TRT; 1.75 mg kg$^{-1}$; sc, 2x/week). Testicular feminized male (Tfm) rats were castrated and given TES therapy (CsX-TRT-Tfm). Data are means ± SEM ($n$ = 6-13 rats per group).

a-c Mean values within each column for BW (week 0, 10, and 15) and seminal vesicle weight without common superscript are significantly different (0.0001 ≤ $P$ ≤ 0.02)

+ , #, * Mean values for BW within each row for each of the experimental groups (InT-control, CsX, CsX-TRT, CsX-DRT, CsX-LST, CsX-LST-TRT, and CsX-TRT-Tfm) over time (week 0, 10, and 15) without common superscript are significantly different (0.0001 ≤ $P$ ≤ 0.02)
Effects of castration and androgen therapy on systolic BP

In the present study, castration of male SD rats produced a progressive increase in systolic BP that attained a plateau after 10-12 weeks that continued through the entire 15 week experimental period. Androgen therapy of CsX rats with either TES or 5α-DS induced vasodilation that continued through the entire 15 week experimental period. Androgen therapy of CsX rats with either TES or 5α-DS produced similar levels of HT in both Wistar and Wistar-Kyoto male rats [49] and that in this model, acute iv infusions of TES and its metabolites produced reductions in the HT [50], although this latter study did not examine long-term effects of androgen therapy on the HT. The results of the present study are the first to demonstrate that both endogenous and exogenous TES exert long-term anti-hypertensive effects in male SD rats. In contrast, there is limited evidence that acute intra-arterial infusions of TES and other androgens produce coronary or systemic vasodilation in vivo in humans [30] and in canine [33], porcine [34, 35], and rodent [36] animal models. In parallel, accumulating evidence from a number of recent animal studies employing isolated blood vessels in vitro, reveals that TES and other androgen metabolites exert beneficial effects by inducing acute vasorelaxation through rapid, nongenomic estrogen-independent mechanisms in a variety of large arteries as well as smaller resistance arteries and at physiological as well as pharmacological concentrations (for reviews, see [31, 32]). Together, these in vitro and in vivo studies reveal that acute androgen-induced vasodilation is a structurally specific, nongenomic effect, with efficacies and potencies fundamentally different than those for the genomic effects of androgens on reproductive targets [31, 37–40]. An intriguing aspect of the structurally specific nongenomic effects of the androgens on vascular function is the effects of the endogenous TES metabolite, 5β-DHT, the stereoisomer of the highly potent androgenic tissue metabolite of TES, 5α-DHT, which is known to mediate the effects of TES in reproductive target tissues. In contrast, 5β-DHT is devoid of genomic androgenic activity at the androgen receptor, but is a highly potent and efficacious nongenomic vasodilator in vitro and in vivo [31, 36] and tissue levels of the enzyme that converts TES to 5β-DHT (5β-reductase) are reduced in patients with essential hypertension [51]. Thus, it is interesting to speculate that the TES metabolite of 5β-reductase, 5β-DHT, which is significantly more potent and efficacious than TES, but without any masculinizing side effects, may be an effective treatment for HT.

Although the mechanisms underlying the acute vasodilatory effects of TES have been established in vitro and to a lesser extent in vivo, little is known about the long-term systemic effects of TES on BP or its underlying mechanisms. To study these mechanism(s), the androgen receptor-deficient Tfm rat was used in the present study to identify possible non-genomic mechanisms contributing to the anti-hypertensive effects of TES. Interestingly, castration of Tfm rats induced long-term HT very similar to that observed in CsX SD male rats, and therapy with TES completely reversed the HT, indeed at a faster rate and to a slightly greater extent than in CsX male SD rats. These findings strongly suggest that the anti-hypertensive effects of endogenous and exogenous TES on systemic BP mainly involve nongenomic mechanisms. Nongenomic mechanisms may involve membrane receptors and include activation of kinase-signaling cascades or modulation of membrane ion channel function. In the present study, there was a progressive increase in systolic BP in both CsX male SD and CsX-Tfm rats; however, there was a delay in the onset of HT in the CsX-Tfm rats, followed by a more rapid increase in the HT which matched that of CsX-SD male rats by week 10, and a more rapid anti-hypertensive response to TES therapy. These differences suggest that interactions between the nongenomic and genomic effects of TES in male SD rats may be responsible for the observed differences between SD and Tfm rats in the development of HT and the anti-hypertensive responses to TES therapy.

Mechanisms underlying anti-hypertensive effects of androgens on systolic BP

The long time-frame for the development of HT in castrated SD male and Tfm rats in the present study suggests that expansion of extracellular fluid volume resulting from the retention of fluid and electrolytes in the absence of TES may contribute to the HT. Thus, the role of RAS function in the development of HT was studied. Interestingly, long-term treatment of CsX male

---

Table 3 Plasma total estrogen and testosterone (TES) of Int-control, CsX, CsX-TRT, CsX-LST, and CsX-LST-TRT male SD rats

| Group          | Total estrogen (pg mL⁻¹) | Testosterone (TES) (ng mL⁻¹) |
|----------------|-------------------------|-----------------------------|
| InT-control    | 30.7 ± 0.6              | 0.72 ± 0.2                  |
| CsX            | 30.9 ± 1.2              | ---- a                      |
| CsX-TRT        | 31.3 ± 0.5              | 0.96 ± 0.1                  |
| CsX-LST        | 32.7 ± 0.2              | ---- a                      |
| CsX-LST-TRT    | 33.2 ± 0.6              | 1.14 ± 0.1                  |

Male Sprague-Dawley (SD) rats: intact (InT-control), bilaterally castrated (CsX), and CsX with TES therapy (CsX-TRT; 1.75 mg kg⁻¹). Data are means ± SEM (n = 6-13 rats per group). Neither total estrogen nor TES concentrations differed significantly among the five experimental groups (P > 0.05).

*Plasma TES levels in CsX and CsX-LST groups were below the detectable limits of the radioimmunoassay.
SD rats with LST, a competitive antagonist of the AT1 receptor, via their drinking water completely prevented the development of HT in these animals over the course of the 15-week experiment, strongly suggesting a role for the RAS in the development of HT in CsX-SD male rats. Consistent with this finding is the elevation in plasma renin concentration observed in these animals, which increased by 38% following CsX. Further support for a role of increased RAS function in the development of HT in these animals is provided by the observed increases in expression of mRNA for renin (92%), AT1R (80%), and ACE (58%) in the kidneys of CsX male SD rats. The observed increases in plasma renin concentration and in expression of renal mRNA for renin, ACE, and AT1R were dramatically reversed following TRT of CsX male SD rats in parallel with the complete reversal of systemic HT over the 5-week course of androgen therapy in these animals. These findings provide strong and consistent evidence that the development of long-term HT in CsX male SD rats in the absence of TES involves upregulation of RAS function in the kidneys of these animals, and that therapy with TES (or DHT) and the reversal of the HT involves inhibition of renal RAS expression by TES. Since there is now good evidence that TES produces systemic hypotension through nongenomically-mediated systemic vasodilation, it is likely that the observed development of HT in CsX male SD rats in the present study involves both the loss of TES-induced systemic vasodilation and expansion of extracellular fluid volume from the retention of fluid and electrolytes resulting from upregulation of renal RAS function in the absence of TES. Preliminary measurements of 24 h urine flow rates in male SD rats suggest that CsX reduces urine flow rate at experimental weeks 4 and 10, compared to Int-control rats, and that initiation of TRT in CsX-SD rats after week 10 measurements increases urine flow rates at weeks 12 and 15; findings consistent with the CsX-induced changes in systolic BP and RAS function (data not shown; ref. [52]). Studies by other investigators support the present hypothesis that the anti-hypertensive effects of TES involve its effects to suppress RAS function and thereby enhance renal fluid and Na+ excretion; thus, earlier studies by Kau et al. revealed that castration-induced loss of TES in male rats increased plasma aldosterone levels by nearly 40%, while TES produced dose-dependent reductions in basal and ACTH-stimulated aldosterone secretion by rat zona glomerulosa cells in primary culture [53]. Similarly, in more recent preliminary studies, expression of mRNA of key Na+ transporters (ENaC, NKCC, NCC, and NHE) in the renal cortex was 0.5-2.5 fold higher in CsX than in intact or CsX-TES male ANGII-hypertensive CD-1 mice [54]. Finally, the cytosolic AR is expressed in both the proximal tubule and cortical collecting duct of human kidneys, clearly implicating the kidney as a target for endogenous androgens [55].

Despite the aforementioned evidence that TES exerts anti-hypertensive effects on the kidney, there is also evidence to the contrary that androgens exert pro-hypertensive effects on the kidney; thus, in vivo renal microperfusion studies by Quan et al. established that 10-day treatment of SD rats with DHT enhanced volume re-absorption in the proximal tubule 38%, expression of the luminal Na+/H+ (NHE3) exchanger 55%, and mean arterial BP 18% [56]. These consistent renal effects of DHT were reduced by inhibition of converting enzyme (Enaliprilat) or blockade of the AT1R (LST), implicating the RAS in the pro-hypertensive effects of DHT. The physiological relevance of these findings is unclear, however, because DHT treatment reduced plasma ANG II levels by 30% and the dose of DHT employed (50 mg/day × 10 days) was dramatically higher than the physiological dose of DHT used in the present study (~ 1.0 mg/week × 5 weeks). Since human and rat kidney tissues both express enzymes involved in androgen biosynthesis and/or are capable of converting precursor compounds to TES and 5α-DHT, local production of androgens within the kidney may also play a role in BP regulation [57, 58].

The fact that HT develops following castration of the androgen receptor-deficient Tfm rats provides strong evidence that the anti-hypertensive effects of TES on the vasculature and kidney rely upon nongenomic mechanism(s) independent of the classic cytosolic AR that mediates the genomic effects of this hormone. In reproductive tissue cultures, AR-independent actions of TES are mediated by membrane receptors that can bind TES, such as the ZIP9 Zinc transporter [59] or other membrane-associated androgen receptor proteins [60]. These receptors appear to mediate the effects of TES via rapid activation of ERK1/2, Akt, and CREB signaling cascades. Similarly, there is evidence that a membrane-associated G protein-coupled TES receptor mediates AR-independent effects as well as modulates genomic effects of TES via ERK1/2/Akt pathways [59–61]. One of these receptors has been associated with beneficial effects of TES in the heart via the PI3/Akt pathway [62]. Since nongenomic mechanisms of TES action appear to involve membrane receptors and intracellular signal transduction cascades, and these signaling mechanisms may also modulate genomic expression, then it is still possible that a combination of genomic as well as nongenomic mechanisms may underlie the antihypertensive effects of endogenous TES in Tfm as well as SD male rats; however, resolution of this possibility must await further studies.

**Physiological relevance of the present findings**

There is a firmly entrenched dogma surrounding CVD that estrogens are protective in females [12–14], whereas
androgens are deleterious in males [9, 10, 15, 16]. These views appear to be based largely on earlier epidemiological data that have driven human clinical and experimental animal studies which support the dogmatic view that TES is deleterious to the heart and vasculature [9–11]; however, many of those past animal studies as well as human studies suffer from flaws or limitations in experimental design and/or the animal models employed [6, 8, 63]. More recently published clinical and experimental studies, as well as the findings of the present study, challenge the TES dogma. Indeed, there is increasing evidence that TES therapy in aging hypogonadal men significantly improves cardiovascular and metabolic functions, including a reduction in diastolic blood pressure [63–65]. Further, plasma TES levels are reduced in both hypertensive men and women [4, 66–68]. It is difficult to reconcile the enigma of beneficial effects of TES reported in more recent clinical studies with the many past experimental animal studies which support the dogma of deleterious effects of TES [17–21], unless more careful scrutiny is applied to these studies. Thus, widely used genetic and induced rat models of HT, such as the spontaneously hypertensive rat (SHR) and Dahl salt-sensitive rat [17, 23] and the DOCA-salt rat [22], respectively, have demonstrated repeatedly that TES does exacerbate HT in males, since castration of males reduces the development of HT. However, these models do so in an unrealistic experimental setting that does not mimic human hypertensive disease, since the effects of TES are determined on a background of established HT (genetic models) or simultaneously developing HT (induced models), rather than on a background of normotension, followed by progressive declines in TES levels and subsequent development of HT, as occurs in human males. Further, the short-term nature of these experiments (often 1-4 weeks) is problematic to the detection of longer term effects of TES on BP in otherwise normal male rats. These limitations may explain why findings from these established models of HT are so incongruous with recent clinical findings from aging human males in which hypogonadism is associated with cardiovascular and metabolic dysfunctions, including hypertension, and that TES therapy is beneficial in reversing these conditions.

Clinical relevance of the present findings
The most recent human clinical trials overwhelmingly report that TRT does not increase cardiovascular risk or mortality in older hypogonadal men and that such therapy is associated with reductions in BP and improvement in metabolic syndrome (e.g., insulin resistance, serum lipids, diabetes, etc.), all of which are risk factors for CVD (for reviews see [63, 69, 70]). Indeed, of nine meta-analyses reported to date, all but one demonstrated that TRT is not harmful and is associated with significant health benefits [69, 70]. The findings of the present study are entirely consistent with these recent human clinical trials, and with much earlier studies in which acute intramuscular injections of TES were used successfully to treat angina pectoris in men with CAD [24–26], and for HT and peripheral vascular disease [26, 27], and were thought to involve vasodilation, and with more recent clinical studies in which intra-arterial infusions of TES produced coronary vasodilation [28–30]. Taken together, the past and present studies strongly suggest that TES and other androgens are, in reality, anti-hypertensive and thus protective against CVD.

Conclusions
The findings of the present study provide important new and novel information on the long-term role of TES in the regulation of systemic BP, and reveal that endogenous androgens exert anti-hypertensive effects that appear to involve non-genomic and possibly genomic mechanisms(s), resulting in reductions in RAS expression in the kidney and enhanced systemic vasodilation. These data further suggest that it is the age-dependent declines in TES levels and the effects of aging in men that exacerbate CVD, not the presence of TES. The effects of aging and hypogonadism on the development of HT in the model developed in the present study await further study, which may serve as a useful translational model to further elucidate the long-term role of TES in cardiovascular and metabolic health and disease.

Perspectives and significance
The long-standing dogmatic view that TES is deleterious to the heart and vasculature [9–11] is challenged by the findings of the present study and by recent clinical findings from aging human males in which hypogonadism is associated with cardiovascular and metabolic dysfunctions, including hypertension, and that TES therapy is beneficial in reversing these conditions. Further understanding of the mechanisms by which TES and other androgens exert beneficial vs. detrimental effects on BP could lead to novel new therapeutic agents to treat HT in the aging male population and reverse symptoms associated with hypogonadism, such as hypertension and metabolic dysfunctions, which are important interactive risk factors for the development of CVD in men.

Abbreviations
ACE: Angiotensin-converting enzyme; Agt: Angiotensinogen; AR: Androgen receptor; AT1: Angiotensin II type 1 receptor; BP: Blood pressure; BW: Body weight; CAD: Coronary artery disease; CVD: Cardiovascular disease; CsX: Castrated; DHT: Dihydrotestosterone; DRT: DHT-replacement therapy; HT: Hypertension; InT: Intact; LST: Losartan; RAS: Renin-angiotensin system; rt-PCR: Real-time polymerase chain reaction; SD: Sprague-Dawley; SV: Seminal vesicles; TES: Testosterone; Tfm: Testicular-feminized male; TRT: TES-replacement therapy
Acknowledgements
The authors thank Dr. Michael Golding for his invaluable assistance in performing RT-PCR measurements of mRNA expression of RAS components in renal and vascular tissue samples. Special thanks to Mr. Nikolas Garcia and Mr. Joshua McKenna for their assistance with the experimental procedures and for valuable discussions during the design and execution of the experiments.

Authors’ contributions
AEH and JNS designed the project. AEH and JNS performed the experiments and analyzed the data. AEH, JNS, and MP interpreted the data and drafted and revised the manuscript. All authors read and approved the final manuscript.

Funding
These studies were supported by the State of Texas (Texas A&M University).

Availability of data and materials
Please contact the corresponding author for data requests.

Ethics approval and consent to participate
The Animal Use Protocol for these studies was written in accordance with regulations of the Office of Laboratory Animal Welfare (OLAW) of the National Institutes of Health (NIH), and were reviewed and approved by the Texas A&M University Institutional Animal Care and Use Committee (IACUC).

Consent for publication
All authors have consented to publication of this manuscript.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Veterinary Physiology and Pharmacology, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, TX 77843-4466, USA. 2 Departamento de Biología Celular y Fisiología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, 04510 México D.F, Mexico. 3 Michael E. DeBakey Institute For Comparative Cardiovascular Sciences, Women’s Health Division, College of Veterinary Medicine, Texas A&M University, College Station, TX 77843-4466, USA.

Received: 26 January 2020 Accepted: 31 July 2020

Published online: 26 August 2020

References
1. Bubbs KJ, Khambata RS, Akhawalla A. Sexual dimorphism in rodent models of hypertension and atherosclerosis. Brit J Pharmacol. 2012;167:298–312.
2. Kalin MF, Zumoff B. Sex hormones and coronary disease: a review of the clinical studies. Steroids. 1990;55:330–52.
3. Kannel WB, and Thom TJ. Incidence, prevalence and mortality and cardiovascular disease. In: The heart. Schlant RC, Alexander RW, New York: McGraw-Hill; 1994.
4. Khaw KT, Barrett-Connor E. Blood pressure and endogenous testosterone in men: an inverse relationship. J Hypertens. 1988;6:329–32.
5. Levy D, Kannel WB. Cardiovascular risks: new insights from Framingham. Am Heart J. 1988;116:266–72.
6. Liu PY, Death AK, Handelsman DJ. Androgens and cardiovascular disease. Endocr Rev. 2003;24:313–40.
7. Messerli FH, Garavaglia GE, Schmieder RE, Sundgaard-Riise K, Nunez BD, Arnedo C. Disparate cardiovascular findings in men and women with essential hypertension. Ann Intern Med. 1987;107:158–61.
8. WU FCW, van Eckardt B. Androgens and coronary artery disease. Endocr Rev. 2003;24:183–217.
9. Hemman SM, Robinson JT, McCredie R, Adams MR, Boyer MJ, Celermajer DS. Androgen deprivation is associated with enhanced endothelium-dependent dilatation in adult men. Arterioscler Thomb Vasc Biol. 1997;17:2004–9.
10. Mendoza SG, Zerpa A, Carrasco H, Colmenares O, Rangel A, Gartsidie PS, et al. Estradiol, testosterone, apolipoproteins, lipoprotein cholesterol, and lipolytic enzymes in men with premature myocardial infarction and angiographically assessed coronary occlusion. Artery. 1983;12:1–23.
11. Reckelhoff JF. Gender differences in the regulation of blood pressure. Hypertension. 2001;37:1199–208.
12. Farhat MY, Lavigne MC, Ramwell PW. The vascular protective effects of estrogen. FASEB J. 1996;10:615–24.
13. Mendelsohn ME, Karas RH. Estrogen and the blood vessel wall. Cur Opin Cardiol. 1994;9:619–26.
14. Opal S. Hormones and vasoprosuction. Hypertension. 1999;33:Pt II:170–6.
15. Chute CG, Baron JA, Pymate SR, Kiel DP, Pavia AT, Lozner EC, et al. Sex hormones and coronary artery disease. Am J Med. 1987;83:853–9.
16. Sewdarsen M, Jalal I, Vythilingum S, Desai R. Sex hormone levels in young Indian patients with myocardial infarction. Arterioscler. 1986;6:418–21.
17. Reckelhoff JF, Zhang H, Granger JP. Testosterone exacerbates hypertension and reduces pressure-natriuresis in male spontaneously hypertensive rats. Hypertension. 1998;31(2):435–9.
18. Ganten U, Schröder G, Witt M, Zimmermann F, Ganten D, Stock G. Sexual dimorphism of blood pressure in spontaneously hypertensive rats effects of anti androgen treatment. J Hypertens. 1989;7:721–6.
19. Crofton JT, Share L. Gonadal hormones modulate deoxycorticosterone-hypertension in male and female rats. Hypertension. 1997;29:949–9.
20. Reckelhoff JF, Zhang H, Sivastava K, Granger JP. Gender differences in hypertension in spontaneously hypertensive rats. Role of androgens and androgen receptor. Hypertension. 1999;34:920–3.
21. Iams SG, Wexler BC. Retardation in the development of spontaneous hypertension in SHR rats by gonadectomy. J Lab Clin Med. 1977;90:997–1003.
22. Crofton JT, Share L, Brooks DP. Gonadectomy abolishes the sexual dimorphism in DOC-salt hypertension in the rat. Clin Exp Hypertens. 1989;11(7):1249–61.
23. Yanes LL, Sartori-Valinotti JC, Iliescu R, Romero DG, Racusen LC, Zhang H, et al. Testosterone-dependent hypertension and upregulation of intrarenal angiotensinogen in dahl salt-sensitive rats. Am J Physiol Ren Physiol. 2009;296:F771–9.
24. Hamm L. Testosterone propionate in the treatment of angina pectoris. J Clin Endocrinol. 1942;2:325–8.
25. Lesser MA. Testosterone propionate therapy in one hundred cases of angina pectoris. J Clin Endocrinol. 1946;5:549–57.
26. Walker TC. Use of testosterone propionate and estrogenic substance in treatment of essential hypertension, angina pectoris, and peripheral vascular disease. J Clin Endocrinol. 1942;2:560–8.
27. Edwards E, Hamilton J, Dunley S. Testosterone propionate as a therapeutic agent in patients with organic disease of peripheral vessels. New Engl J Med. 1939;220:865–9.
28. Jaffe MD. Effect of testosterone cypionate on postexercise ST segment depression. Br Heart J. 1939;19:117–22.
29. Rosano GVC, Leonardo F, Pagnotta P, Pelliccia F, Panina G, Cerquetani E, et al. Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation. 1999;99:1664–70.
30. Webb CM, McNeill JG, Hayward CS, de Zeigler D, Collins P. Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation. 1999;100:1690–6.
31. Perusquia M, Stallone JD. Do androgens play a beneficial role in the regulation of vascular tone? Nongenomic vascular effects of testosterone metabolites. Am J Physiol Heart Circ Physiol. 2010;298:H1301–7.
32. Nettleship JE, Jones RD, Channer KS, Jones TH. Testosterone and coronary artery disease. Front Horm Res. 2009;37:91–107.
33. Chou TM, Sudhir K, Hamilton J, Duntley S. Testosterone propionate as a therapeutic agent in patients with organic disease of peripheral vessels. New Engl J Med. 1939;220:865–9.
34. Molinari C, Battaglia A, Grosini E, Mary DA, Vassanelli C, Vacca G. The effect of testosterone on regional blood flow in prepubertal anesthetized pigs. J Physiol. 2002;543:365–72.
35. Molinari C, Battaglia A, Grosini E, Mary DA, Vassanelli C, Vacca G. The effects of dehydroepiandrosterone in regional blood flow in prepubertal anesthetized pigs. J Physiol. 2004;557:307–19.
36. Perusquia M, Greenway CD, Perkins LM, Stallone JD. Systemic hypertensive effects of testosterone are androgen structure-specific and neuronal nitric oxide synthase-dependent. Am J Physiol Regul Integr Comp Physiol. 2015;309:R189–95.
37. Ding AQ, Stallone JD. Testosterone-induced relaxation of rat aorta is androgen structure specific and involves K+ channel activation. J Appl Physiol. 2001;91:2742–50.
38. Perusquia M, Navarrete E, Gonzalez L, Villalón CM. The modular role of androgens and progestins in the induction of vasorelaxation in human umbilical artery. Life Sci. 2007;81:1993–1002.

39. Perusquia M, Villalón CM. The vasodilator effect of androgens in pituitary rat pituitary cell cultures: potential role of calcium channels. Steroids. 2002;67:1021–8.

40. Yue P, Chatterjee K, Beale C, Poole-Wilson PA, Collins P. Testosterone relaxes rabbit coronary arteries and aorta. Circulation. 1995;91:1154–60.

41. Li M, Stallone JN. Estrogen potentiates vasopressin-induced contraction of rat renal arteries by enhancing cyclooxygenase-2 and thromboxane function. Am J Physiol Heart Circ Physiol. 2005;289(4):H1542–50.

42. Stanley AJ, Gumbreck LG, Allison JE, Easley RB. Part I. male pseudohermaphroditism in the laboratory Norway rat. Recent Prog Horm Res. 1973;29:930–60.

43. Shapiro BH, Levine DC, Adler NT. The testicular feminized rat: a naturally occurring model of androgen independent brain masculinization. Science. 1980;209(4454):418–20.

44. Yarbrough WG, Quarmby VE, Simental JA, Joseph DR, Sar M, Lubahn DB, et al. A single base mutation in the androgen receptor gene causes androgen insensitivity in the testicular feminized rat. J Biol Chem. 1990;265(15):8893–900.

45. Stallone JN, Salisbury RL, Fulton CT. Androgen receptor defect abolishes sex differences in nitric oxide and reactivity to vasopressin in rat aorta. J Appl Physiol. 2001;91:2602–10.

46. Costarella CE, Stallone JN, Rutecki GW, Whittier FC. Testosterone causes direct relaxation of rat thoracic aorta. J Pharmacol Exp Ther. 1996;277(1):34–9.

47. Bolvin GP, Hickman DL, Creamer-Hente MA, Pritchett-Coming KR, Bratcher NA. Review of COX as a euthanasia agent for laboratory rats and mice. J Am Assoc Lab Anim Sci. 2017;56(5):491–9.

48. Chang RC, Skiles WM, Cronister SS, Wang H, Sutton GI, Bedi YS, et al. DNA methylation-independent growth restriction and altered developmental programming in a mouse model of preconception male alcohol exposure. Epigenetics. 2017;12(10):841–53.

49. Perusquia M, Herrera N, Ferrer M, Stallone JN. Antihypertensive effects of androgens in conscious, spontaneously hypertensive rats. J Steroid Biochem Mol Biol. 2017;167:106–14.

50. Perusquia M, Contreras D, Herrera N. Hypotestosteronemia is an important factor for the development of hypertension: elevated blood pressure in orchidectomized conscious rats is reversed by different androgens. Endocrine. 2019;65(2):146–55.

51. Ih K, Myamori I, Hatakeyama H, Yoneda T, Takeda Y, Takeda R, et al. The activities of 5 beta-reductase and 11 beta-hydroxysteroid dehydrogenase in essential hypertension. Steroids. 1994;59:656–60.

52. Hanson AE, Garcia NW, McKenna JM, Perusquia M, Stallone JN. Hypotestosteronemia-induced hypertension in male Sprague-Dawley rats is reversed by testosterone replacement therapy, which is a non-genomic, estrogen-independent effect. FASEB J. 2018;32(1):584.9.

53. Kau M-M, Lo M-J, Wang S-W, Tsai S-C, Chen J-J, Chiao Y-C, et al. The essential hypertension in male Sprague-Dawley rats: potential role of calcium channels. Steroids. 2002;67:1021–8.

54. Yue P, Chatterjee K, Beale C, Poole-Wilson PA, Collins P. Testosterone relaxes rabbit coronary arteries and aorta. Circulation. 1995;91:1154–60.

55. Matsuzaki K, Arai T, Inumaru T, Mihori M, Momose T, Sano M, et al. Androgen metabolism in cultured rat renal inner medullary collecting duct (IMCD) cells. Steroids. 1998;63:105–10.

56. Bulldan A, Malviya VN, Upmanyu N, Konrad L, Scheiner-Bobis G. Testosterone/bicalutamide antagonism at the predicted extracellular androgen binding site of ZIP9. BBA-Mol Cell Res. 1862;2017:2402–14.

57. Peinetti N, Scalari M, Rubio MMC, Leimgruber C, Nicola JP, Torres AI, et al. The response of prostate smooth muscle cells to testosterone is determined by the subcellular distribution of the androgen receptor. Endocrinology. 2018;159(2):945–56.

58. Chodari L, Mohammadi M, Mohaddes G, Alipour MR, Ghorbanzaade V, Darlushima N, et al. Testosterone and voluntary exercise, alone or together, increase cardiac activation of AKT and ERK1/2 in diabetic rats. Arq Bras Cardiol. 2016;107(6):532–41.

59. Zhao J, Liu GL, Wei Y, Jiang LH, Bao PL, Yang QY. Low-dose testosterone alleviates vascular damage caused by castratation in male rats in puberty via modulation of the PI3K/AKT signaling pathway. Mol Med Rep. 2016;14(3):2518–26.

60. Triash AM, Haider A, Haider KS, Doros G, Saad F. Long-term testosterone therapy improves cardiometabolic function and reduces risk of cardiovascular disease in men with hypogonadism: a real-life observational registry study setting comparing treated and untreated (control) groups. J Cardiovasc Pharmacol Therap. 2017;22(5):414–33.

61. Fogari R, Preti P, Zoppi A, Fogari E, Rinaldi A, Corradi L, et al. Serum testosterone levels and arterial blood pressure in the elderly. Hypertens Res. 2005;28:625–30.

62. Mäkin P, Holmberg S, Johnsson L, Sjöstrom L, Kvist H, Holm G, et al. The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obes Relat Metab Disord. 1992;16:991–7.

63. Hughes GS, Mathur RS, Margolius HS. Sex steroid hormones are altered in essential hypertension. J Hypertens. 1989;7:181–7.

64. Phillips GB, Jing TY, Resnick LM, Barbagallo M, Laragh JH, Sealey JE. Sex hormones and hemostatic risk factors for coronary heart disease in men with hypertension. J Hypertens. 1993;11:699–702.

65. Svartberg J, von Mühlen D, Schirmer H, Baretz-Connor E, Sundfjord J, Jordie R. Association of endogenous testosterone with blood pressure and left ventricular mass in men. The Tromso study. Eur J Endocrinol. 2004;150:655–71.

66. Morgentaler A, Miner MM, Caliber M, Guay AT, Khera M, Triash AM. Testosterone therapy and cardiovascular risk: advances and controversies. Mayo Clin Proc. 2015;90(2):224–51.

67. Morgentaler A, Zitmann M, Triash AM. Fundamental concepts regarding testosterone deficiency and treatment: international expert consensus resolutions. Mayo Clin Proc. 2016;91(7):881–96.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.